(Q82407168)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

7

Karin Milde-Langosch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Linn Woelber

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Volkmar Mueller

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christine Eulenburg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Joerg Schwarz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Walter Carney

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Fritz Jaenicke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sven Mahner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

6 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

183-188

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

Cancer's craving for sugar: an opportunity for clinical exploitation

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Therapeutic applications of glycosidic carbonic anhydrase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Expression of MaTu-MN protein in human tumor cultures and in clinical specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Analysis of potential prognostic factors in 111 patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

New tumor markers: CA125 and beyond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Potential markers that complement expression of CA125 in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Inhibition of carbonic anhydrase IX: a new strategy against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

Adjuvant therapy for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.029

10.1016/J.YGYNO.2009.11.029

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20051287%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference